Topical corticosteroid therapy: clobetasol propionate 0.025%

Authors

  • Waseem Y. Syed Department of Dermatology, Skin Wellness Clinic, Ratnagiri, Maharashtra, India
  • Minal A. Ranade Department of Dermatology, Ranade Clinic, MG Road, Lonavala, Pune, Maharashtra, India
  • Anshu Agarwal Department of Dermatology, Nayako Ko Mohalla, Sikar, Rajasthan, India
  • Pankaj Kumar Department of Dermatology, Skin Care Clinic, Madhubani, Bihar, India
  • Surjit S. Mehta Department of Dermatology, Maharaja Agarsen Hospital, Punjabi Bagh, West Delhi, India
  • Yeluri V. R. L. M. Deexith Department of Dermatology, Dr. Umachand Hospitals, Kavali, Andhra Pradesh, India
  • Devendra Jain Department of Dermatology, Pratham Skin and Hair Care Centre, Virar West, Palghar, Maharashtra, India
  • Nirmal K. Saini Department of Dermatology, Skin Care Clinic, Sri Ganganagar, Rajasthan, India
  • Sanjeev S. Patil Department of Dermatology, Dr. Patil's Skin Clinic, Vijayapura, Karnataka, India
  • Parag A. Talavia Department of Dermatology, Skin Laser and Cosmetic Center, Gondal, Gujarat, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20223654

Keywords:

Clobetasol propionate 0.025%, Psoriasis, Plaque psoriasis, Topical corticosteroids

Abstract

Topical corticosteroids have been the cornerstone of treatment over the last six decades for various dermatoses characterized by dry, scaly, crusted, or erythematous skin as well as those associated with inflammation and pruritus. The potency of a topical steroid depends on the specific molecule, the amount of drug reaching the target, absorption through the skin (0.25%–3%), and the formulation. Clobetasol propionate (CP) 0.025% cream formulation is a potent, fifth-generation topical corticosteroid. It is approved by the United States Food and Drug Administration to be applied twice daily for the treatment of moderate-to–severe psoriasis in adults. This case series covers the clinical experience of various dermatologists, including their expert opinion on the safety and efficacy of ImpoyzTM (CP) cream 0.025% in different skin disorders.

References

Abidi A, Ahmad F, Singh SK. A comparative clinical evaluation of once daily versus alternate day application of topical clobetasol propionate cream in psoriasis. J Clin Diagn Res. 2013;7(1):100-5.

Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154-71.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis-A review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Desai S, Draelos Z, Feldman S, Jackson JM. A phase 3, randomized, double-blind, vehicle-controlled, multicenter, parallel group trial investigating the efficacy and safety of clobetasol propionate cream, 0.025% in the treatment of moderate to severe plaque psoriasis for 14 days. SKIN J Cutaneous Med. 2021;5(6):s33.

Downloads

Published

2022-12-30

How to Cite

Syed, W. Y., Ranade, M. A., Agarwal, A., Kumar, P., Mehta, S. S., Deexith, Y. V. R. L. M., Jain, D., Saini, N. K., Patil, S. S., & Talavia, P. A. (2022). Topical corticosteroid therapy: clobetasol propionate 0.025%. International Journal of Research in Medical Sciences, 11(1), 316–322. https://doi.org/10.18203/2320-6012.ijrms20223654

Issue

Section

Case Series